ATE135907T1 - Stabile arzneimittel mit 3-(hydroxymethyl)-5,5- diphenylhydantoin-dinatrium-phosphatester - Google Patents

Stabile arzneimittel mit 3-(hydroxymethyl)-5,5- diphenylhydantoin-dinatrium-phosphatester

Info

Publication number
ATE135907T1
ATE135907T1 AT90908752T AT90908752T ATE135907T1 AT E135907 T1 ATE135907 T1 AT E135907T1 AT 90908752 T AT90908752 T AT 90908752T AT 90908752 T AT90908752 T AT 90908752T AT E135907 T1 ATE135907 T1 AT E135907T1
Authority
AT
Austria
Prior art keywords
diphenylhydantoin
hydroxymethyl
dinatrium
phenytoin
phosphate esters
Prior art date
Application number
AT90908752T
Other languages
English (en)
Inventor
Dale E Herbranson
Earl R Speicher
Leonard S Rosenberg
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Application granted granted Critical
Publication of ATE135907T1 publication Critical patent/ATE135907T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90908752T 1989-05-25 1990-05-24 Stabile arzneimittel mit 3-(hydroxymethyl)-5,5- diphenylhydantoin-dinatrium-phosphatester ATE135907T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/356,948 US4925860A (en) 1987-08-05 1989-05-25 Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester

Publications (1)

Publication Number Publication Date
ATE135907T1 true ATE135907T1 (de) 1996-04-15

Family

ID=23403641

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90908752T ATE135907T1 (de) 1989-05-25 1990-05-24 Stabile arzneimittel mit 3-(hydroxymethyl)-5,5- diphenylhydantoin-dinatrium-phosphatester

Country Status (28)

Country Link
US (1) US4925860A (de)
EP (1) EP0473687B1 (de)
JP (1) JP3143471B2 (de)
KR (1) KR0143768B1 (de)
AT (1) ATE135907T1 (de)
AU (1) AU632130B2 (de)
CA (1) CA2067122A1 (de)
CZ (1) CZ277918B6 (de)
DE (2) DE69026253T2 (de)
DK (1) DK0473687T3 (de)
ES (1) ES2086404T3 (de)
FI (1) FI101041B (de)
HK (1) HK1006807A1 (de)
HU (1) HU212944B (de)
IE (1) IE81130B1 (de)
IL (1) IL94504A (de)
LU (1) LU90340I2 (de)
MX (1) MX9203584A (de)
MY (1) MY106190A (de)
NL (1) NL980045I2 (de)
NO (1) NO179124C (de)
NZ (1) NZ233808A (de)
PT (1) PT94161B (de)
RU (1) RU2075973C1 (de)
SG (1) SG64881A1 (de)
SK (1) SK277911B6 (de)
WO (1) WO1990014080A1 (de)
ZA (1) ZA904038B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU624262B2 (en) * 1989-08-10 1992-06-04 Warner-Lambert Company Use of prophenytoin for treating stroke
ES2169375T3 (es) * 1996-04-30 2002-07-01 Warner Lambert Co Proceso mejorado para la sintesis de diesteres del ester 2,5-dioxo-4,4-difenil-imidazolidin-1-ilmetilico de acido fosforico.
WO1998056422A1 (en) * 1997-06-13 1998-12-17 The University Of Kansas Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
WO1999004798A1 (en) * 1997-07-22 1999-02-04 Warner-Lambert Company Lyophilized fosphenytoin sodium for parenteral use
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
EP1153010A1 (de) 1999-02-08 2001-11-14 Checkpoint Genetics, Inc. N-substituierte aminosäuren, pharmazeutische antioxidant-zusammensetzungen die diese enthalten und verfahren zu ihrer anwendung
WO2001000191A2 (en) * 1999-06-23 2001-01-04 Warner-Lambert Company Use of fosphenytion for the treatment of acute neuropathic pain
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
US20070244074A1 (en) * 2006-04-17 2007-10-18 Sougata Pramanick Stable parenteral formulation of fosphenytoin sodium
KR101303088B1 (ko) * 2009-02-17 2013-09-06 한림제약(주) 3-(히드록시메틸)-5,5-디페닐히단토인 이나트륨 포스페이트에스테르를 함유하는 주사용 약학 조성물
ES3031438T3 (en) 2009-06-25 2025-07-08 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2011163594A2 (en) 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
EP3718536A1 (de) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit verbesserter lagerstabilität
CN103288877B (zh) * 2013-05-10 2016-03-09 安徽省先锋制药有限公司 磷苯妥英稳定的有机胺盐及其制备方法和用途
EP3119399A4 (de) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazolformulierungen mit erhöhten injektionsgeschwindigkeiten
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
JP7720391B2 (ja) 2020-12-04 2025-08-07 シーチュアン クレジット ファーマシューティカル カンパニー リミテッド フォスフェニトインナトリウム固体組成物、凍結乾燥法、及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins

Also Published As

Publication number Publication date
EP0473687A4 (en) 1992-12-02
SK277911B6 (en) 1995-07-11
CZ277918B6 (en) 1993-06-16
NO179124B (no) 1996-05-06
RU2075973C1 (ru) 1997-03-27
NO914582D0 (no) 1991-11-22
HUT61198A (en) 1992-12-28
NL980045I2 (nl) 1999-07-01
WO1990014080A1 (en) 1990-11-29
CA2067122A1 (en) 1990-11-26
DE19975021I2 (de) 2004-07-01
HK1006807A1 (en) 1999-03-19
DE69026253T2 (de) 1996-09-19
NO179124C (no) 1996-08-14
MX9203584A (es) 1992-07-01
SG64881A1 (en) 1999-11-16
EP0473687B1 (de) 1996-03-27
NO914582L (no) 1991-11-22
JP3143471B2 (ja) 2001-03-07
ES2086404T3 (es) 1996-07-01
KR920700628A (ko) 1992-08-10
CS9002566A2 (en) 1991-10-15
IE81130B1 (en) 2000-03-22
KR0143768B1 (ko) 1998-07-15
PT94161A (pt) 1991-01-08
NZ233808A (en) 1992-04-28
HU212944B (en) 1996-12-30
IL94504A (en) 1994-06-24
LU90340I2 (fr) 1999-03-19
IL94504A0 (en) 1991-03-10
AU5670490A (en) 1990-12-18
MY106190A (en) 1995-03-31
ZA904038B (en) 1992-01-29
PT94161B (pt) 1996-12-31
FI101041B (fi) 1998-04-15
FI915491A0 (fi) 1991-11-21
JPH05504544A (ja) 1993-07-15
DE69026253D1 (en) 1996-05-02
IE901872L (en) 1990-11-25
DK0473687T3 (da) 1996-08-05
EP0473687A1 (de) 1992-03-11
NL980045I1 (nl) 1999-03-01
AU632130B2 (en) 1992-12-17
US4925860A (en) 1990-05-15

Similar Documents

Publication Publication Date Title
DE19975021I2 (de) Stabile Arzneimittel mit 3-(hydroxymethyl)-5,5-diphenylhydantoin-dinatrium-phosphatester.
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
GB8819110D0 (en) Antihypertensive drug & method for production
IT1276225B1 (it) Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
ATE121295T1 (de) Augentropfenarzneimittel.
NO179671C (no) Substituerte cykloheksanderivater, anvendelse av disse for fremstilling av legemidler samt legemiddel for behandling type II diabetes og andre sykdommer
ATE147265T1 (de) Verwendung von retinoiden zur umkehr glucocorticoid-induzierter hautatrophie
NO303715B1 (no) Stabilt, vandig apparat
NO301767B1 (no) Salt av clavulansyre
BE893492A (fr) Procede de preparation d'esters d'acides apovincaminiques, esters ainsi obtenus et compositions pharmaceutiques prepares avec ces esters
ATE179889T1 (de) Arzneimittel, die ester omega-3 polyungesättigter säuren enthalten und deren verwendung in der topischen behandlung morbider erkrankungen
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
BR9304151A (pt) Soluçao de injeçao da mesma, processo para sua produçao, aplicaçao dessa coluçâo e produto farmaceutico para evitar o efeito colateral de oxazafosforina
BR0013563A (pt) Preparação farmacêutica sólida, utilização de uma preparação farmacêutica e processo para a produção de uma preparação farmacêutica
GR1001133B (el) Μέ?οδος παρασκευής στα?ερής σύν?εσης δινατρίου άλατος φωσφορικού εστέρος 3-(υδροξυμε?υλο)-5,5-διφαινυλουδαντοϊνης.
IT1244728B (it) Impiego medicamentoso di derivati diidropiridinici
ITMI940696A0 (it) Derivati dell'acido fosfonico utili nel trattamento delle malattie cardiovascolari
ITMI911842A0 (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
ITMI912027A0 (it) Derivati dell'eserolina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
ITMI911841A0 (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
ITMI911713A0 (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
IT1263913B (it) Composti terapeuticamente attivi, utili per il trattamento di malattieconnesse con alterata funzionalita' del sistema immunitario, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
BR9204459A (pt) Derivados de aminoacidos e processo para a sua producao,compostos,medicamentos,uso dos ditos derivados e processo para tratar ou prevenir pressao sanguinea elevada e/ou insuficiencia cardlaca